101 related articles for article (PubMed ID: 26205693)
1. Novel structural co-expression analysis linking the NPM1-associated ribosomal biogenesis network to chronic myelogenous leukemia.
Chan LW; Lin X; Yung G; Lui T; Chiu YM; Wang F; Tsui NB; Cho WC; Yip SP; Siu PM; Wong SC; Yung BY
Sci Rep; 2015 Jul; 5():10973. PubMed ID: 26205693
[TBL] [Abstract][Full Text] [Related]
2. Coexpression Pattern Analysis of NPM1-Associated Genes in Chronic Myelogenous Leukemia.
Wang F; Chan LW; Tsui NB; Wong SC; Siu PM; Yip SP; Yung BY
Biomed Res Int; 2015; 2015():610595. PubMed ID: 25961029
[TBL] [Abstract][Full Text] [Related]
3. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
4. The molecular biology of chronic myeloid leukaemia.
Melo JV
Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
[TBL] [Abstract][Full Text] [Related]
5. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia molecular signature.
Nowicki MO; Pawlowski P; Fischer T; Hess G; Pawlowski T; Skorski T
Oncogene; 2003 Jun; 22(25):3952-63. PubMed ID: 12813469
[TBL] [Abstract][Full Text] [Related]
7. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
[TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
9. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism.
Raimondo S; Saieva L; Corrado C; Fontana S; Flugy A; Rizzo A; De Leo G; Alessandro R
Cell Commun Signal; 2015 Feb; 13():8. PubMed ID: 25644060
[TBL] [Abstract][Full Text] [Related]
11. Analysis of microRNA and gene networks in human chronic myelogenous leukemia.
Wang K; Xu Z; Wang N; Tian Y; Sun X; Ma Y
Mol Med Rep; 2016 Jan; 13(1):453-60. PubMed ID: 26548770
[TBL] [Abstract][Full Text] [Related]
12. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
13. Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.
Supper E; Tahir S; Imai T; Inoue J; Minato N
PLoS One; 2015; 10(7):e0134026. PubMed ID: 26218064
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.
Peng J; Zuo Z; Fu B; Oki Y; Tang G; Goswami M; Priyanka P; Muzzafar T; Medeiros LJ; Luthra R; Wang SA
Eur J Haematol; 2016 Jan; 96(1):65-71. PubMed ID: 25809997
[TBL] [Abstract][Full Text] [Related]
15. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
16. Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia.
Zheng Y; Wang YP; Cao H; Chen Q; Zhang X
Mol Med Rep; 2018 Aug; 18(2):1766-1772. PubMed ID: 29901125
[TBL] [Abstract][Full Text] [Related]
17. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
18. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
Dilloo D; Hanenberg H; Lion T; Burdach S
Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Wu HK; Minden MD
Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
